CIK 0001845459
NKGN NKGen Biotech, Inc.
Insider trading from SEC Form 4. Last filing Dec 26, 2024.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
4
with a Form 4 at this company
Signals
Open-market buys and sells at NKGen Biotech, Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 17 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 20, 2024 | Graf James A Interim CFO | JOther Common Stock | -63,634 | $0.00 | $0 | 2,082,507 | Dec 26, 2024 |
| Dec 20, 2024 | Graf James A Interim CFO | DDisposition to issuer Private Placement Warrantsderivative | -757,942 | - | - | 1,145,831 | Dec 26, 2024 |
| Dec 20, 2024 | Graf James A Interim CFO | DDisposition to issuer Working Capital Warrantsderivative | -93,334 | - | - | 96,472 | Dec 26, 2024 |
| Dec 2, 2024 | Graf James A Interim CFO | JOther Common Stock | -97,232 | $0.00 | $0 | 2,339,512 | Dec 23, 2024 |
| Dec 16, 2024 | Graf James A Interim CFO | JOther Common Stock | -83,214 | $0.00 | $0 | 2,256,298 | Dec 23, 2024 |
| Dec 18, 2024 | Graf James A Interim CFO | JOther Common Stock | -110,157 | $0.00 | $0 | 2,146,141 | Dec 23, 2024 |
| Dec 2, 2024 | Graf James A Interim CFO | DDisposition to issuer Private Placement Warrantsderivative | -713,357 | - | - | 4,008,176 | Dec 23, 2024 |
| Dec 16, 2024 | Graf James A Interim CFO | DDisposition to issuer Private Placement Warrantsderivative | -1,212,707 | - | - | 2,795,469 | Dec 23, 2024 |
| Dec 16, 2024 | Graf James A Interim CFO | DDisposition to issuer Working Capital Warrantsderivative | -66,667 | - | - | 456,473 | Dec 23, 2024 |
| Dec 18, 2024 | Graf James A Interim CFO | DDisposition to issuer Private Placement Warrantsderivative | -891,696 | - | - | 1,903,773 | Dec 23, 2024 |
| Dec 18, 2024 | Graf James A Interim CFO | DDisposition to issuer Working Capital Warrantsderivative | -266,667 | - | - | 189,806 | Dec 23, 2024 |
| Dec 6, 2024 | Graf James A Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +500,000 | $0.00 | $0 | 500,000 | Dec 10, 2024 |
| Dec 6, 2024 | Klowden Michael director | AGrant or award Stock Option (right to buy)derivative | +300,000 | $0.00 | $0 | 300,000 | Dec 10, 2024 |
| Dec 6, 2024 | Song Paul Y. Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +2,000,000 | $0.00 | $0 | 2,000,000 | Dec 10, 2024 |
| Dec 6, 2024 | Scott Kathleen D. director | AGrant or award Stock Option (right to buy)derivative | +300,000 | $0.00 | $0 | 300,000 | Dec 10, 2024 |
| Dec 6, 2024 | Klowden Michael director | AGrant or award Stock Option (right to buy)derivative | +500,000 | $0.00 | $0 | 500,000 | Dec 10, 2024 |
| Dec 6, 2024 | Scott Kathleen D. director | AGrant or award Stock Option (right to buy)derivative | +500,000 | $0.00 | $0 | 500,000 | Dec 10, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Graf James AChief Financial Officer
- Klowden Michaeldirector
- Scott Kathleen D.cfo, officer, director
- Song Paul Y.Chief Executive Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.